Patrizia Alessi
Papers
1
Total Citations
44
H-Index
1
About
Patrizia Alessi is a leading figure in the field of bioconjugation and targeted cancer therapeutics, with a particular focus on antibody-directed enzyme prodrug therapy (ADEPT). Her seminal 2004 work, which has garnered 44 citations, established a groundbreaking strategy by engineering a thermostable human prolyl endopeptidase. This enzyme, expressed and purified from *E. coli*, is designed to selectively activate prodrugs—where cytotoxic agents are masked by a proline-containing peptide—directly at tumor sites. By harnessing the specificity of post-proline cleaving endopeptidases, Alessi’s approach minimizes systemic toxicity while maximizing local drug efficacy, representing a significant advance over conventional chemotherapy. Her contributions have not only refined the ADEPT platform but also opened new avenues for designing safer, more precise cancer treatments. Through her innovative work, Alessi has demonstrated how protein engineering can be leveraged to overcome key limitations in drug delivery, making her a pivotal researcher in the intersection of enzymology and oncology.
Research Focus
Key Achievements
Top Papers
- 1